Magazine Article | August 1, 2023

Companies To Watch: Ventoux Biosciences

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader
Follow Me On Twitter @WayneKoberstein

Pursuing drug treatments for all sufferers of Dupuytren’s and other fibroproliferative diseases

Ventoux Biosciences is an early-stage biopharma startup in preclinical development of medications for treating Dupuytren’s disease (palmar fibromatosis) and related fibrotic diseases. The company is developing two lead candidates, coded VEN-201 and VEN-202, for the same indications: Dupuytren’s, which causes painful deformities in the hand, and Ledderhose disease (plantar fibromatosis), which produces hard growths on the bottom of the foot.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader